New hope for advanced cancers: first human trial of NUV-1511 begins

NCT ID NCT06334432

First seen Feb 01, 2026 · Last updated May 09, 2026 · Updated 14 times

Summary

This study tests a new drug called NUV-1511 in people with advanced solid tumors that have not responded to other treatments. The trial has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors in specific cancers like breast, prostate, pancreatic, and ovarian cancer. About 466 adults will take part to see if NUV-1511 can help control their disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Carolina BioOncology Institute

    Huntersville, North Carolina, 28078, United States

  • Fred Hutchinson

    Seattle, Washington, 98109, United States

  • Hackensack University Medical Center

    Hackensack, New Jersey, 07601, United States

  • Karmanos Cancer Center

    Detroit, Michigan, 48201, United States

  • Memorial Sloan-Kettering Cancer Center

    New York, New York, 10065, United States

  • NEXT Oncology

    Irving, Texas, 75038, United States

  • NEXT Oncology

    Fairfax, Virginia, 22031, United States

  • START Mountain

    Salt Lake City, Utah, 84124, United States

Conditions

Explore the condition pages connected to this study.